COMMUNIQUÉS West-GlobeNewswire

-
Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH
24/01/2025 - 22:05 -
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
24/01/2025 - 22:01 -
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
24/01/2025 - 22:00 -
Bilan semestriel du contrat de liquidité de la société Inventiva conclu avec Kepler Cheuvreux
24/01/2025 - 22:00 -
Press release: Sequana Medical Announces New Share Capital Amount and New Number of Shares following Loan Conversions
24/01/2025 - 19:30 -
AB Science will host a live webcast on Tuesday January 28, 2025, from 5.30pm to 6.45pm CET
24/01/2025 - 18:01 -
AB Science tiendra une conférence virtuelle le mardi 28 janvier 2025, de 17h30 à 18h45
24/01/2025 - 18:01 -
Elevar Therapeutics Presents Results from Post-Hoc Analysis of CARES-310 Study Evaluating the Impact of Viral and Non-Viral Etiology on Survival in Hepatocellular Carcinoma
24/01/2025 - 16:41 -
Beyond Air® Announces LungFit® PH Receives Market Authorization in Australia
24/01/2025 - 15:15 -
Privia Health to Report Fourth Quarter 2024 Results on Thursday, February 27
24/01/2025 - 15:00 -
Positron Corporation Secures Agreement to Sell and Rent Eight NeuSight PET-CT Scanners
24/01/2025 - 15:00 -
Firefly Neuroscience Announces Publications Demonstrating the Utility of Advanced EEG Analytics in Drug Development and Neuropsychiatric Care
24/01/2025 - 15:00 -
Autonomix Medical, Inc. (NASDAQ: AMIX) Announces Release of the Next CEO Corner Segment
24/01/2025 - 14:45 -
Cannabix and AlcoPro Enter MOU for Marijuana Breathalyzer Marketing
24/01/2025 - 14:45 -
SoftSmile and ClearCorrect Announce Settlement
24/01/2025 - 14:28 -
475,000 members and counting: HOOPP adds 33 new employers in 2024
24/01/2025 - 14:00 -
Gelteq Appoints Matthew Jones as Head of Sports Performance
24/01/2025 - 14:00 -
Sword Health Acquires Surgery Hero to Accelerate Global Growth and Expand its Presence in the UK
24/01/2025 - 13:46 -
X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor for the Treatment of WHIM Syndrome
24/01/2025 - 13:36
Pages